Bulevirtide is an antiviral medication for treating chronic hepatitis delta (HDV) infection. In this interview, we speak with Prof. Pietro Lampertico (University of Milan, Milan, Italy), about the clinical trial data surrounding this treatment and what the results mean for clinical practice.
The abstracts entitled ‘Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel design study’ (GS006) and ‘Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta’ (SAT352) were presented at EASL ILC  ILC 2022, 22-26 June.
Questions
- Could you tell us a little about chronic hepatitis delta viral (HDV) infection, its health burden and the unmet needs in its treatment? (0:32)
- What is the mechanism of action of bulevirtide? (1:44)
- Could you give us a brief overview of the phase 2 and phase 3 clinical trials? (2:28)
- How do you think the recent phase 3 results will impact clinical practice? (3:45)
Disclosures: Prof. Pietro Lampertico has acted as consultant/advisory board member/speaker for, and/or received honoraria from BMS, Roche, Gilead, GSK, AbbVie, MSD, Arrowhead, Alnylam, Janssen, SBring Bank, MYR, Eiger, Antios, Aligos and VIR.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Please click here for related content
